标签归档：dihydrate

Tauroursodeoxycholate dihydrate(Synonyms: 牛磺熊去氧胆酸二水合物; Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Tauroursodeoxycholate dihydrate (Synonyms: 牛磺熊去氧胆酸二水合物; Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate) 纯度: ≥98.0%

Tauroursodeoxycholate (Tauroursodeoxycholic acid; TDUCA) dihydrate 是一种内质网应激抑制剂。Tauroursodeoxycholate 显著降低凋亡分子如 caspase-3 和 caspase-12 表达。Tauroursodeoxycholate 也抑制 ERK。

Tauroursodeoxycholate dihydrate(Synonyms: 牛磺熊去氧胆酸二水合物; Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate)

Tauroursodeoxycholate dihydrate Chemical Structure

CAS No. : 117609-50-4

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥660 In-stock
50 mg ￥600 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Tauroursodeoxycholate dihydrate 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Immunology/Inflammation Compound Library
  • Kinase Inhibitor Library
  • MAPK Compound Library
  • Metabolism/Protease Compound Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Human Endogenous Metabolite Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Reprogramming Compound Library
  • Oxygen Sensing Compound Library
  • Endoplasmic Reticulum Stress Compound Library
  • Glutamine Metabolism Compound Library
  • Neurodegenerative Disease-related Compound Library
  • Angiogenesis Related Compound Library
  • Food-Sourced Compound Library
  • Anti-Liver Cancer Compound Library
  • Rare Diseases Drug Library
  • Anti-Colorectal Cancer Compound Library

生物活性

Tauroursodeoxycholate (Tauroursodeoxycholic acid; TDUCA) dihydrate is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK[1][2].

IC50 & Target

ERK[1]
Caspase-3, Caspase-12[2]
Clinical Trial

分子量

535.73

Formula

C26H49NO8S
CAS 号

117609-50-4
中文名称

牛磺熊脱氧胆酸二水合物；牛磺熊去氧胆酸二水合物
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 83.33 mg/mL (155.54 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.8666 mL 9.3331 mL 18.6661 mL
5 mM 0.3733 mL 1.8666 mL 3.7332 mL
10 mM 0.1867 mL 0.9333 mL 1.8666 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (3.88 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.88 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (3.88 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.88 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (3.88 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.88 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Kim SY, et al. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK viaPKCα-mediated MKP-1 induction. Cardiovasc Res. 2011 Nov 1;92(2):307-16.

    [2]. Qin Y, et al. Tauroursodeoxycholic Acid Attenuates Angiotensin II Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-deficient Mice by Inhibiting Endoplasmic Reticulum Stress. Eur J Vasc Endovasc Surg. 2017 Mar;53(3):337-345.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Quercetin dihydrate

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Quercetin dihydrate  纯度: ≥96.0%

Quercetin dihydrate 是一种天然黄酮类化合物，可激活或抑制许多蛋白质的活性。Quercetin (dihydrate) 可激活 SIRT1，也可抑制 PI3K，抑制 PI3K γ，PI3K δ，PI3K β 的 IC50 值分别为 2.4 μM, 3.0 μM, 5.4 μM。

Quercetin dihydrate

Quercetin dihydrate Chemical Structure

CAS No. : 6151-25-3

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥440 In-stock
500 mg ￥400 In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Quercetin dihydrate 相关产品

•相关化合物库:

  • Natural Product Library Plus
  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Immunology/Inflammation Compound Library
  • Kinase Inhibitor Library
  • PI3K/Akt/mTOR Compound Library
  • Stem Cell Signaling Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Differentiation Inducing Compound Library
  • Oxygen Sensing Compound Library
  • Medicine Food Homology Compound Library
  • Phenols Library
  • Glycolysis Compound Library
  • Cytoskeleton Compound Library
  • Orally Active Compound Library
  • Traditional Chinese Medicine Monomer Library
  • FDA Approved & Pharmacopeial Drug Library
  • Flavonoids Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Angiogenesis Related Compound Library
  • Glucose Metabolism Compound Library
  • Food-Sourced Compound Library
  • Anti-Liver Cancer Compound Library
  • Rare Diseases Drug Library
  • Anti-Colorectal Cancer Compound Library

生物活性

Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].

IC50 & Target[1]

PI3Kγ

2.4 μM (IC50)

PI3Kβ

5.4 μM (IC50)

PI3Kδ

3.0 μM (IC50)

体外研究
(In Vitro)

Quercetin dihydrate is a type of plant-based chemical, or phytochemical, used as an ingredient in supplements, beverages or foods. In several studies, it may have anti-inflammatory and antioxidant properties, and it is being investigated for a wide range of potential health benefits[1].
Quercetin dihydrate is a PI3K inhibitor with IC50s of 2.4-5.4 μM. Quercetin dihydrate strongly abrogates PI3K and Src kinases, mildly inhibits Akt1/2, and slightly affected PKC, p38 and ERK1/2[1].
Quercetin dihydrate inhibits TNF-induced LDH% release, EC-dependent neutrophils adhesion to bovine pulmonary artery endothelial cells (BPAEC), and BPAEC DNA synthesis and proliferation[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

338.27

Formula

C15H14O9
CAS 号

6151-25-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (295.62 mM; Need ultrasonic)

H2O : < 0.1 mg/mL (insoluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.9562 mL 14.7811 mL 29.5622 mL
5 mM 0.5912 mL 2.9562 mL 5.9124 mL
10 mM 0.2956 mL 1.4781 mL 2.9562 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.39 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.39 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Navarro-Núñez L, et al. Effect of quercetin on platelet spreading on collagen and fibrinogen and on multiple platelet kinases. Fitoterapia. 2010 Mar;81(2):75-80.

    [2]. Yu XB, et al. Inhibitory effects of protein kinase C inhibitors on tumor necrosis factor induced bovine pulmonary artery endothelial cell injuries. Yao Xue Xue Bao. 1996;31(3):176-81.

    [3]. Yang F, et al. Combination of Quercetin and 2-Methoxyestradiol Enhances Inhibition of Human Prostate Cancer LNCaP and PC-3 Cells Xenograft Tumor Growth. PLoS One. 2015 May 26;10(5):e0128277.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Tetrahydrouridine dihydrate(Synonyms: 四氢尿苷; THU dihydrate; NSC-112907 dihydrate)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Tetrahydrouridine dihydrate (Synonyms: 四氢尿苷; THU dihydrate; NSC-112907 dihydrate)

Tetrahydrouridine dihydrate (THU dihydrate) 是一种有效的胞苷脱氨酶 (CDA) 抑制剂，竞争性阻断酶的活性位点。

Tetrahydrouridine dihydrate(Synonyms: 四氢尿苷; THU dihydrate; NSC-112907 dihydrate)

Tetrahydrouridine dihydrate Chemical Structure

规格 价格 是否有货
568 μg (100 mM * 20 μL in Water) ￥500 询问价格 & 货期
1420 μg (100 mM * 50 μL in Water) ￥1050 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Tetrahydrouridine dihydrate (THU dihydrate) is potent inhibitor of cytidine deaminase (CDA), which competitively blocks the enzyme’s active site more effectively than intrinsic cytidine.

IC50 & Target

cytidine deaminase (CDA)[1]
体外研究
(In Vitro)

Tetrahydrouridine (THU) is a specific inhibitor of cytidine deaminase (CDA) which can suppress deamination in the catabolism of cytotoxic deoxycytidine analogues like ara-C and Gemcitabine. To test how Tetrahydrouridine affects the Gemcitabine-mediated anti-neoplastic effect on pancreatic and lung carcinoma cells, a combination therapy is performed. As expected, high CDA expression in BxPC-3 and H441 results in improved Gemcitabine sensitivity after a 100 µM Tetrahydrouridine treatment. The sensitivity of BxPC-3 and H441 cell lines increases by as much as approximately 2.1 and 4.4 fold respectively. On the other hand, MIAPaCa-2 and H1299 cells unexpectedly become more sensitive to Gemcitabine with low CDA expression. MIAPaCa-2 and H1299 cells show a change in IC50 of 2.2 and 2.3 fold respectively. However, Panc-1 and H322 cells do not show significant changes in drug sensitivity. These data suggested that Tetrahydrouridine can sensitize some pancreatic and lung carcinoma cells to Gemcitabine-induced cell death regardless of CDA expression levels. Tetrahydrouridine inhibits S-phase without apoptosis[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Administration of 167 mg/kg Tetrahydrouridine (THU) followed by 1.0 mg/kg DAC results in death in one male and eight females. Animals surviving to scheduled termination are generally asymptomatic with no treatment related effects observed in body weights, food consumption, clinical chemistry and urinalysis for a treatment up to 1.0 mg/kg DAC in combination with 167 mg/kg Tetrahydrouridine in animals[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

284.26

Formula

C9H20N2O8
中文名称

四氢尿苷
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Solution, -20°C, 2 years
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (351.79 mM)

H2O : 50 mg/mL (175.90 mM; Need ultrasonic)

* “≥” means soluble, but saturation unknown.

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.79 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.79 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.79 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Funamizu N, et al. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels. PLoS One. 2012;7(5):e37424.

    [2]. Terse P, et al. Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Int J Toxicol. 2014 Mar-Apr;33(2):75-85.
Cell Assay
[1]

Cell growth for pancreatic and lung carcinoma cell lines is carried out using the colorimetric methylene blue assay in 96-well plates at a density of 5,000 cells/well. Cells are either exposed or not exposed to Tetrahydrouridine (100 µM), counting the first 12 hrs as Day 0. Mean values are calculated from three different wells in triplicates for four days[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[2]

Mice[2]
CD-1 mice (male 30-38 g and female 24-31g) from are individually housed in polycarbonate cages suspended on stainless steel racks with SaniChip certified hardwood bedding. Mice are assigned to four dose groups and a vehicle control group. Animals are gavaged with DAC or its vehicle 1 hour ± 5 minutes after administration of THU or its vehicle at a dose volume of 10 mL/kg. The DAC doses are selected based on the range finding study in which the mice tolerated six oral doses (2x/week) of 0.1, 0.2 and 0.4 mg/kg DAC in combination with a fixed dose of 167 mg/kg THU. A fixed Tetrahydrouridine dose (500 mg/m2) and the optimal timing between Tetrahydrouridine and DAC administration (60 min) are selected. Conversion of milligrams per body surface area dose in mice into milligrams per kilogram body weight dose estimation is based on Michaelis constant (km) values for mice obtained from US Food and Drug Administration published guidelines. In brief, the mouse dose in milligrams per body surface area (500 mg/m2) is divided by the km of 3 to convert the dose to milligrams per kilogram body weight (167 mg/kg).

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Funamizu N, et al. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels. PLoS One. 2012;7(5):e37424.

    [2]. Terse P, et al. Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Int J Toxicol. 2014 Mar-Apr;33(2):75-85.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Cas(117772-70-0), Azithromycin Dihydrate, 阿齐霉素,Azithromycin Dihydrate,

发表于由

阿奇霉素 二水合物

大环内酯类抗生素
≥98%

有货

Cas(117772-70-0), Azithromycin Dihydrate, 阿齐霉素,Azithromycin Dihydrate,

CAS编号 117772-70-0 | 品牌：Jinpan
Azithromycin Dihydrate

MSDS

质检证书(CoA)

相似产品

  • 分子式 C38H72N2O12·2H2O
  • 分子量785.02
  • MDL号 MFCD01862248

货号 (SKU) 包装规格 是否现货 价格 数量
E129935-1g 1g 现货 Cas(117772-70-0), Azithromycin Dihydrate, 阿齐霉素,Azithromycin Dihydrate,  
E129935-5g 5g 现货 Cas(117772-70-0), Azithromycin Dihydrate, 阿齐霉素,Azithromycin Dihydrate,  
E129935-25g 25g 现货 Cas(117772-70-0), Azithromycin Dihydrate, 阿齐霉素,Azithromycin Dihydrate,  

基本信息

产品名称 阿奇霉素 二水合物
英文名称 Azithromycin Dihydrate
别名 阿齐霉素
英文别名 N-Methyl-11-aza-10-deoxo-10-dihydroerythromycin A
规格或纯度 ≥98%
运输条件 冰袋运输
生化机理 大环内酯类抗生素。细菌50S核糖体抑制剂。抑制细菌细胞的翻译，细胞活力和生长速率（IC 50 = 0.4μg/ ml）。对革兰氏阴性和革兰氏阳性细菌具有口服活性。

一般描述

An azalide antimicrobial agent active in vitro against various pathogens.

Azithromycin dihydrate has anti-immunomodulatory/anti-inflammatory properties, which make it useful in treating cystic fibrosis. It shows an azalide antimicrobial agent active in vitro against various pathogens.

相关属性

CAS编号 117772-70-0
敏感性 对空气敏感
比旋光度 -47° (C=2,EtOH)
熔点 126℃
沸点 717℃
溶解性 DMSO 100 mg/mL Water 10 mg/mL Ethanol 100 mg/mL
储存温度 2-8°C储存,充氩
RTECS RN6960000
MDL号 MFCD01862248
分子量 785.02
分子式 C38H72N2O12·2H2O
品牌 Jinpan
备注 如果有可能，您尽量在同一天配置溶液，并在当天使用完它。但是，如果您需要预先配制储备溶液，我们建议您将溶液等份保存在-20°C的密封小瓶中。通常，它们最多可以使用一个月。在使用前和打开样品瓶之前，我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度，用法和处理的建议吗？请访问我们的常见问题（FAQ）页面以获取更多详细信息。

Nitroprusside disodium dihydrate(Synonyms: 硝普钠二水合物; Sodium nitroprusside dihydrate; Sodium Nitroferricyanide(III) Dihydrate)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Nitroprusside disodium dihydrate (Synonyms: 硝普钠二水合物; Sodium nitroprusside dihydrate; Sodium Nitroferricyanide(III) Dihydrate) 纯度: 99.72%

Nitroprusside disodium dehydrate (Sodium nitroprusside dihydrate) 是一种血管扩张剂，用于急性高血压、心力衰竭的研究。Nitroprusside disodium dehydrate 可在谷胱甘肽耗竭的成骨细胞中诱导自噬。Nitroprusside disodium dehydrate 在大鼠肠缺血再灌注模型中能作为一氧化氮 (NO) 供体。

Nitroprusside disodium dihydrate(Synonyms: 硝普钠二水合物; Sodium nitroprusside dihydrate; Sodium Nitroferricyanide(III) Dihydrate)

Nitroprusside disodium dihydrate Chemical Structure

CAS No. : 13755-38-9

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥550 In-stock
500 mg ￥500 In-stock
10 g ￥600 In-stock
50 g   询价  

* Please select Quantity before adding items.

Nitroprusside disodium dihydrate 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Drug Repurposing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Targeted Diversity Library

生物活性

Nitroprusside disodium dehydrate (Sodium nitroprusside dihydrate) is a vasodilator that available for the research of acute hypertension, heart failure. Nitroprusside disodium dehydrate induces autophagy in glutathione-depleted osteoblasts. Nitroprusside disodium dehydrate acts as a nitric oxide (NO) donor in a rat intestinal ischemia reperfusion model[1][2][3][4].

体外研究
(In Vitro)

Nitroprusside disodium dehydrate sensitizes human gastric cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis[4].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

297.95

Formula

C5H0.4FeN6Na2O1.2
CAS 号

13755-38-9
中文名称

硝普酸钠 (二水)；二水合硝普化钠
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
溶解性数据
In Vitro: 

H2O : 100 mg/mL (335.63 mM; Need ultrasonic)

DMSO : 50 mg/mL (167.81 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.3563 mL 16.7813 mL 33.5627 mL
5 mM 0.6713 mL 3.3563 mL 6.7125 mL
10 mM 0.3356 mL 1.6781 mL 3.3563 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： PBS

    Solubility: 100 mg/mL (335.63 mM); Clear solution; Need ultrasonic

  • 2.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (8.39 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.39 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 3.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (8.39 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.39 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. J N Cohn, et al. Nitroprusside. Ann Intern Med. 1979 Nov;91(5):752-7.

    [2]. Namazi, H., Sodium nitroprusside as a nitric oxide donor in a rat intestinal ischemia reperfusion model: a novel molecular mechanism. Clinics (Sao Paulo), 2008. 63(3): p. 405.

    [3]. Min Jeong Son, et al. Sodium nitroprusside induces autophagic cell death in glutathione-depleted osteoblasts. J Biochem Mol Toxicol. Sep-Oct 2010;24(5):313-22.

    [4]. Liuqin Yang, et al. Sodium nitroprusside (SNP) sensitizes human gastric cancer cells to TRAIL-induced apoptosis. Int Immunopharmacol. 2013 Oct;17(2):383-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Quinidine sulfate dihydrate(Synonyms: 硫酸奎尼宁)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Quinidine sulfate dihydrate (Synonyms: 硫酸奎尼宁)

Quinidine sulfate dihydrate 是一种抗心律失常剂，也是 K+ 通道 (K+ channel) 的有效阻断剂，其 IC50 值为 19.9 μM。Quinidine sulfate dihydrate 是一种有效且选择性的细胞色素 P450db (cytochrome P450db) 抑制剂，也可用作疟疾的研究。

Quinidine sulfate dihydrate(Synonyms: 硫酸奎尼宁)

Quinidine sulfate dihydrate Chemical Structure

CAS No. : 6591-63-5

规格 是否有货
5 mg 询价
10 mg 询价
25 mg 询价

* Please select Quantity before adding items.

生物活性

Quinidine sulfate dihydrate is a potent and selective inhibitor of cytochrome P450db and inhibits amphetamine metabolism in vivo[1]. Quinidine sulfate dihydrate enhances the cytotoxicity of vincristine (VCR) in tumor cells and especially in VCR-resistant sublines of P388 leukemia (P388/VCR) and human myelogenous leukemia[2].

IC50 & Target

IC50: cytochrome P450db; amphetamine metabolism[1]
Clinical Trial

分子量

405.50

Formula

C21H30N2O7S
CAS 号

6591-63-5
中文名称

硫酸奎尼宁
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. David E. Moody, et al. Quinidine Inhibits In Vivo Metabolism of Amphetamine in Rats: Impact upon Correlation between GCIMS and Immunoassay Findings in Rat Urine. ournal of Analytical Toxicology, Vol. 14, September/October 1990

    [2]. Tsuruo T, et al. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells.Cancer Res. 1984 Oct;44(10):4303-7.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Tolmetin sodium dihydrate(Synonyms: 痛灭定)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Tolmetin sodium dihydrate (Synonyms: 痛灭定) 纯度: 99.89%

Tolmetin sodium dehydrate 是一种具有口服活性的，有效的 COX 抑制剂，对人 COX-1 和 COX-2 的 IC50 值分别为 0.35 µM 和 0.82 µM。Tolmetin sodium dehydrate 属于非甾体类物质，具有强效的抗炎活性。

Tolmetin sodium dihydrate(Synonyms: 痛灭定)

Tolmetin sodium dihydrate Chemical Structure

CAS No. : 64490-92-2

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥550 In-stock
100 mg ￥500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Tolmetin sodium dihydrate 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Ferroptosis Compound Library
  • Anti-COVID-19 Compound Library
  • NMPA-Approved Drug Library
  • Pyroptosis Compound Library
  • Orally Active Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

Tolmetin sodium dihydrate is an orally active and potent COX inhibitor with IC50s of 0.35 µM and 0.82 µM human COX-1 and COX-2, respectively. Tolmetin sodium dihydrate is a non-steroidal anti-inflammatory drug (NSAID)[1][2].

IC50 & Target[1]

Human COX-1

0.35 μM (IC50)

Human COX-2

0.82 μM (IC50)

体外研究
(In Vitro)

Tolmetin sodium dihydrate (0.25 mM) does not attenuate lipid peroxidation in rat brain homogenate. Tolmetin (0.25, 0.5, 0.75, 1 mM) shows radical scavenging properties but without superoxide anion generation in rat brain homogenat[3].
Tolmetin sodium dihydrate (0.001-100 μM) shows anticancer activity againts HT-29 colon cancer cell line in a dose-dependent manner[4].
Tolmetin sodium dihydrate (0-100 μM) shows no effect on osteoblast growth[5].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Tolmetin sodium dihydrate (30,100 mg/kg; gavage; single dose or twice daily for 3 and 14 days) shows maximal ulcerogenic effect 4 h after the single dose, while potently decreases after 3 and 14 days of repeated administration in male Wistar rats weighing 180-200 g. Tolmetin causes gastric lesions in 100 mg/kg[2].
Tolmetin sodium dihydrate (5 mg/kg twice a day for 5 days) pre-treatment considerably attenuates quinolinic acid (QA)-induced neurotoxicity[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

315.30

Formula

C15H18NNaO5
CAS 号

64490-92-2
中文名称

托美丁钠二水；痛灭定；托麦汀钠二水
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

H2O : ≥ 100 mg/mL (317.16 mM)

DMSO : 12.5 mg/mL (39.64 mM; Need ultrasonic)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.1716 mL 15.8579 mL 31.7158 mL
5 mM 0.6343 mL 3.1716 mL 6.3432 mL
10 mM 0.3172 mL 1.5858 mL 3.1716 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 1.25 mg/mL (3.96 mM); Clear solution

    此方案可获得 ≥ 1.25 mg/mL (3.96 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 1.25 mg/mL (3.96 mM); Clear solution

    此方案可获得 ≥ 1.25 mg/mL (3.96 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 1.25 mg/mL (3.96 mM); Clear solution

    此方案可获得 ≥ 1.25 mg/mL (3.96 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. T D Warner, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7563-8.

    [2]. Morini G, et al. Morphological features of rat gastric mucosa after acute and chronic treatment with amtolmetin guacyl: comparison with non-selective and COX-2-selective NSAIDs. Digestion. 2003;68(2-3):124-32. Epub 2003 Nov 7.

    [3]. Dairam A, et al. Non-steroidal anti-inflammatory agents, tolmetin and sulindac, attenuate oxidative stress in rat brain homogenate and reduce quinolinic acid-induced neurodegeneration in rat hippocampal neurons. Metab Brain Dis. 2006 Sep;21(2-3):221-33.

    [4]. DADAŞ, Yakup, et al. Synthesis and anticancer activity of some novel tolmetin thiosemicarbazides. Marmara Pharmaceutical Journal 19(3) • April 2015

    [5]. Etcheverry SB, et al. Three new vanadyl(IV) complexes with non-steroidal anti-inflammatory drugs (Ibuprofen, Naproxen and Tolmetin). Bioactivity on osteoblast-like cells in culture. J Inorg Biochem. 2002 Jan 1;88(1):94-100.
Animal Administration
[1]

Rats[1]
After 2 weeks of acclimatization, rats are randomized to different groups and given the non-selective COX inhibitors, amtolmetin guacyl (AMG) (50 and 150 mg/kg) and Tolmetin (30 and 100 mg/kg) as well as the selective COX-2 inhibitor, celecoxib (CXIB; 20 and 60 mg/kg). The compounds are suspended in 1% carboxymethylcellulose (CMC) immediately before use and administered by gavage in a 10-mL/kg volume. Control groups receive CMC in the same volume. Rats from each group are divided into 3 subgroups, consisting each of at least 10 animals. Subgroups are dosed either with a single dose (acute treatment group) or twice daily for 3 and 14 days (chronic treatment groups). To ensure that all groups are dosed for the same period of time, those receiving less than 14 days of NSAIDs are given CMC until they are due to start the assigned treatment. Rats are killed by cervical dislocation 4 h after the last administration. Stomachs are immediately removed, opened along the lesser curvature and gently rinsed[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. T D Warner, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7563-8.

    [2]. Morini G, et al. Morphological features of rat gastric mucosa after acute and chronic treatment with amtolmetin guacyl: comparison with non-selective and COX-2-selective NSAIDs. Digestion. 2003;68(2-3):124-32. Epub 2003 Nov 7.

    [3]. Dairam A, et al. Non-steroidal anti-inflammatory agents, tolmetin and sulindac, attenuate oxidative stress in rat brain homogenate and reduce quinolinic acid-induced neurodegeneration in rat hippocampal neurons. Metab Brain Dis. 2006 Sep;21(2-3):221-33.

    [4]. DADAŞ, Yakup, et al. Synthesis and anticancer activity of some novel tolmetin thiosemicarbazides. Marmara Pharmaceutical Journal 19(3) • April 2015

    [5]. Etcheverry SB, et al. Three new vanadyl(IV) complexes with non-steroidal anti-inflammatory drugs (Ibuprofen, Naproxen and Tolmetin). Bioactivity on osteoblast-like cells in culture. J Inorg Biochem. 2002 Jan 1;88(1):94-100.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Tartaric acid disodium dihydrate(Synonyms: Sodium tartrate dibasic dihydrate; Sodium tartrate dihydrate)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Tartaric acid disodium dihydrate (Synonyms: Sodium tartrate dibasic dihydrate; Sodium tartrate dihydrate) 纯度: ≥98.0%

酒石酸钠二元二水合物是一种钠盐, 在分子生物学和细胞培养中用作缓冲液, 是酸性磷酸酶抑制剂, 增加秋水仙碱结合tubulin1率。

Tartaric acid disodium dihydrate(Synonyms: Sodium tartrate dibasic dihydrate; Sodium tartrate dihydrate)

Tartaric acid disodium dihydrate Chemical Structure

CAS No. : 6106-24-7

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in Water ￥550 In-stock
500 mg ￥500 In-stock
5 g ￥600 In-stock
10 g   询价  
50 g   询价  

* Please select Quantity before adding items.

Tartaric acid disodium dihydrate 相关产品

•相关化合物库:

  • Natural Product Like Compound Library
  • Bioactive Compound Library Plus
  • Metabolism/Protease Compound Library
  • Anti-Cancer Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Gut Microbial Metabolite Library
  • Phosphatase Inhibitor Library
  • Microbial Metabolite Library
  • Food Additive Library
  • Food-Sourced Compound Library
  • Inactive Ingredient Library

生物活性

Tartaric acid disodium dihydrate is a Acid phosphatase inhibitor, is a sodium salt used in buffers for molecular biology and cell culture applications. Increases the rate of colchicine binding to tubulin1.

分子量

232.10

Formula

C4H10Na2O8
CAS 号

6106-24-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
溶解性数据
In Vitro: 

H2O : 100 mg/mL (430.85 mM; Need ultrasonic)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 4.3085 mL 21.5424 mL 43.0849 mL
5 mM 0.8617 mL 4.3085 mL 8.6170 mL
10 mM 0.4308 mL 2.1542 mL 4.3085 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Erythromycin A dihydrate

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Erythromycin A dihydrate 

Erythromycin A dihydrate 是由放线菌产生的大环内酯类抗生素 (antibiotic)，具有广泛的抗菌活性。Erythromycin A dihydrate 通过结合细菌的 50S 核糖体亚基而起作用，并通过阻断转肽和/或易位反应来抑制 RNA 依赖性蛋白 (RNA-dependent protein synthesis) 的合成，而不会影响核酸的合成。Erythromycin A dihydrate 在不同领域的研究中显示出抗肿瘤特性和保护神经的作用。

Erythromycin A dihydrate

Erythromycin A dihydrate Chemical Structure

CAS No. : 59319-72-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Erythromycin A dihydrate 的其他形式现货产品:

Erythromycin

生物活性

Erythromycin A dihydrate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin A dihydrate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid[1][2]. Erythromycin A dihydrate also exhibits antitumor and neuroprotective effect in different fields of research[3][4].

IC50 & Target

Bacterial; RNA-dependent protein synthesis[1]
体外研究
(In Vitro)

Erythromycin A dihydrate inhibits growth of P. falciparum with IC50 and IC90 values of 58.2 μM and 104.0 μM, respectively[1].
Erythromycin A dihydrate (10 μM, 100 μM; 24 h, 72 h) shows antioxidant and anti-inflammatory effects and suppresses the accumulation of 4-HNE (p<0.01) and 8-OHdG (p<0.01), reduces Iba-1 (p<0.01) and TNF-α (p<0.01) expression significantly[4].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[4]

Cell Line: Embryos primary cortical neuron (from the cerebral cortices of 17-day-old Sprague-Dawley rat)
Concentration: 10, 100 μM
Incubation Time: 24, 72 hours
Result: Improved the viability of cultured neuronal cells in vitro after 3 hours oxygen-glucose deprivation (OGD).

体内研究
(In Vivo)

Erythromycin A dihydrate (gastric intubation; 0.1-50 mg/kg; 30-120 days) decreases tumor growth and prolong the survival time of mice from dose of 5 mg/kg in mice[3].
Erythromycin A dihydrate (gastric intubation; 5 mg/kg) protects mice alive even at 120 days after inoculation, but shortens mean survival time in tumor-bearing mice by 4-5 days with dose of 50 mg/kg[3].
Erythromycin A dihydrate (i.h.; single injection; 50 mg/kg) has a protective effect on the rat model with cerebral ischemia reperfusion-injury[4].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female ddY mice at the age of 6 weeks with EAC cells or CDF mice at the age of 6 weeks with P388 cells[3]
Dosage: 0.1 mg/kg; 0.5 mg/kg; 10 mg/kg; 30 mg/kg; 50 mg/kg
Administration: Gastric intubation; 30-120 days
Result: Decreased tumor growth and prolonged the mean survival time of mice from the dose of 5 mg/kg, however, the 50 mg/kg dosage shortened the MST in tumorbearing mice.
Animal Model: Male Sprague-Dawley rats (8-week-old, 250-300 g)[4]
Dosage: 50 mg/kg
Administration: Subcutaneous single injection
Result: Reduced infarct volume and edema volume, improved neurological deficit.

Clinical Trial

分子量

769.96

Formula

C37H71NO15
CAS 号

59319-72-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Gribble MJ, et al. Erythromycin. Med Clin North Am. 1982 Jan;66(1):79-89.

    [2]. Nakornchai S, et al. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 2006 Dec;100(3):185-91. Epub 2006 Nov 28.

    [3]. K Hamada, et al. Antitumor Effect of Erythromycin in Mice. Chemotherapy

    [4]. Katayama Y, et al. Neuroprotective effects of erythromycin on cerebral ischemia reperfusion-injury and cell viability after oxygen-glucose deprivation in cultured neuronal cells. Brain Res. 2014 Nov 7. 1588:159-67.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务